arrow
M

Muhammad Bilal Abid

Texas Tech University Health Science Center
H指数:24
被引数:2,266

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence Synthesis

标准治疗方案伊达匹单抗 vedotin(Idecabtagene Vicleucel)用于复发/难治性多发性骨髓瘤后出现的髓外疾病和长期血液毒性:一项跨大西洋真实世界证据综合

2026-10-220
OA
Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug–Interaction Analysis of the FDA Adverse Event Reporting System

替雷利珠单抗联合达雷木单抗在复发或难治性多发性骨髓瘤中的感染并发症和毒性的分析:FDA不良事件报告系统的不成比例性和药物相互作用分析

Cancers
IF4.4
2026-10-210
OA
Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article

去中心化CAR-T生产:临床、经济和监管视角。世界血液与骨髓移植网络(WBMT)专题文章

2026-09-240
PRE
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma

与贝antasine相比,氟达拉滨作为大细胞淋巴瘤CAR-T治疗前淋巴清除化疗的比较

2026-06-240
PREAI
The intricate interplay of microbial metabolomics and carcinogenesis: a spotlight on mechanistic pathways; clinical implications and methodological challenges

微生物代谢组学与致癌作用之间错综复杂的相互作用:聚焦机制通路;临床意义与方法学挑战

2026-05-290
OAAI
Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

嵌合抗原受体T细胞疗法治疗高级别B细胞淋巴瘤NOS

2025-07-220
PRE
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR

CD19嵌合抗原受体T细胞疗法治疗大B细胞淋巴瘤后的感染:CIBMTR的真实世界分析

2025-05-300
OAAI
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings
2025-01-211
OAAI
Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

种族和民族对脐血移植后结局的影响

2024-10-010
PRE
Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis

多剂量SARS-CoV-2疫苗对接受嵌合抗原受体T细胞治疗的b细胞恶性血液病患者的疗效: 一项当代队列分析

2024-03-016
OAAI
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
2023-11-177
OAAI
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis

≥ 1年异基因造血干细胞移植幸存者长期结果的种族和社会经济差异: CIBMTR分析

2023-11-016
PRE
Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

在接受异基因造血干细胞移植的老年b细胞急性淋巴细胞白血病患者中,与年长的同胞供者相比,年轻的匹配的无关供者的复发风险降低

2023-10-0115
OAAI
Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia

供者年龄对老年急性髓系白血病异基因造血干细胞移植结局的影响

2023-09-0112
OAAI